[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Fundación IVI\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":98},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,67],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100053326","curendo-cord-blood-uterine-regeneration-endometrium-platelet-rich-plasma-therapy-derived-from-umbilical-cord-blood-for-the-treatment-of-endometrial-pathologies-asherman-syndrome--endometrial-atrophy--thin-endometrium-100053326",false,"NCT07697924","CURENDO (Cord-blood Uterine Regeneration Endometrium): Platelet-rich Plasma Therapy Derived From Umbilical Cord Blood for the Treatment of Endometrial Pathologies (Asherman Syndrome \u002F Endometrial Atrophy \u002F Thin Endometrium)","CURENDO","Inclusion Criteria:\n\n* age between 18 and 48 years at the time of recruitment\n* body mass index (BMI): ≥ 18 kg\u002Fm2 and ≤ 35 kg\u002Fm2\n* endometrial thickness \\\u003C 5 mm despite estrogen administration according to each clinic's routine practice for 10 or more days and\u002For evidence of Asherman syndrome.\n\nExclusion Criteria:\n\n* Active genital infection at the time of recruitment\n* chronic endometritis\n* known endometrial pathology\n* psychiatric disorder that could hinder study follow-up\n* positive results on viral safety testing (HBsAg, HBcAb, HCV, HIV-1, HIV-2, syphilis)\n* presence of any syndrome or condition that, in the opinion of the principal investigator, could pose a risk to the study or to the patient\n* any clinically significant abnormality detected during the recruitment process\n* simultaneous participation in another clinical study that could affect the objectives of the present study, or prior participation in this same study.","FEMALE","18 Years","48 Years",{"count":20,"type":21},35,"ESTIMATED","INTERVENTIONAL",[24],"NA","In recent years, platelet-rich plasma (PRP) has emerged as a promising alternative for treating endometrial pathologies that affect the endometrial lining. Several studies have tested this therapeutic approach in human patients, but the results are inconclusive. Moreover, in recent years, different investigations have suggested that PRP derived from umbilical cord blood (hUC-PRP) contains a higher concentration of growth factors and other pro-regenerative molecules than PRP obtained from adult peripheral blood. In our previous pilot study conducted in 15 patients with endometrial atrophy\u002FAsherman syndrome\u002Fthin endometrium, preliminary results indicate that hysteroscopic injection of hUC-PRP increases endometrial thickness and improves the endometrial pattern. For this reason, the present study aims to corroborate our previous findings by increasing the number of patients to 35, in prior HRT cycles in these women, to gain a deeper understanding of the effectiveness of this new therapy.",[27],"Asherman Syndrome","RECRUITING","2026-07-09",{"date":31,"type":32},"2026-07-13","ACTUAL",{"date":34,"type":32},"2025-12-18",{"date":36,"type":21},"2029-12",{"name":38,"class":39},"Fundación IVI","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},"100565506","the-influence-of-the-vaginal-microbiome-on-clinical-pregnancy-in-patients-undergoing-a-euploid-embryo-transfer-100565506","NCT06643065","The Influence of the Vaginal Microbiome on Clinical Pregnancy in Patients Undergoing a Euploid Embryo Transfer","The Influence of the Vaginal Microbiome on Clinical Pregnancy in Patients Undergoing a Euploid Embryo Transfer: A Prospective Blinded Multicentre Cohort Study","Inclusion Criteria:\n\n* ART patients undergoing the transfer of a euploid embryo\n\nExclusion Criteria:\n\n* Patients with a body mass index (BMI) ≥35\n\n  * Patients with uncorrected uterine malformations\n  * Patients with a unicornuate uterus\n  * Patients with a bicornuate uterus\n  * Patients with any type of submucosal myoma\n  * Patients with an intramural myoma if ≥4 cm\n  * Patients with severe adenomyosis (\\>50% of the uterine corpus affected as defined by the MUSA criteria \\[19\\])\n  * Patients undergoing transfer of an embryo with a morphology score \\\u003C4BC (according to the Gardner \\& Schoolcraft scoring system \\[18\\])\n  * Patients undergoing transfer of a day-7 embryo\n  * Patients who took antibiotics in the month prior to the embryo transfer (excluding antibiotics given following oocyte retrieval)","50 Years",{"count":50,"type":21},1573,"OBSERVATIONAL","Microorganisms such as bacteria live naturally on and in the bodies and are of great importance for our health. In the female body, almost 10% of all microorganisms live in the reproductive organs and especially in the vagina. Healthy bacteria in the vagina can defend against harmful bacteria and infections. However, it occasionally happens that the balance between healthy and harmful bacteria is disturbed, and it is believed that this could potentially harm pregnancy. However, there is not much evidence to prove a connection between an imbalance in bacteria and having an unsuccessful pregnancy.\n\nFor this reason, the goal of our study is to determine if women with certain vaginal bacteria are more likely to experience pregnancy failures. If the investigators find this to be true, patients undergoing fertility treatment might be recommended regular tests in the future. If an imbalance in bacteria is found, doctors could provide treatment to restore a healthy vaginal environment, potentially improving the chances of a successful pregnancy.",[54],"Vaginal Microbiome",[56,57],"Female reproductive tract microbiome,","Vaginal dysbiosis","2026-06-29",{"date":60,"type":32},"2026-06-30",{"date":62,"type":32},"2024-07-17",{"date":64,"type":21},"2027-09-30",{"name":38,"class":39},10,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":75,"sex":16,"minAge":17,"maxAge":76,"enrollmentInfo":77,"targetDuration":79,"studyType":51,"phases":4,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":40},"100537648","impact-of-ivf-hormonal-therapy-on-endometrial-receptivity-and-endometrial-senescent-cell-pathological-accumulation-100537648","NCT06280560","Impact of IVF Hormonal Therapy on Endometrial Receptivity and Endometrial Senescent Cell Pathological Accumulation","Impact of Controlled Ovarian Stimulation and Luteal Phase Support on Endometrial Receptivity and Endometrial Senescent Cell Pathological Accumulation: Pilot Study","HormoSenoRec","Study group (subfertile IVF patients).\n\n* Inclusion Criteria: Women aged 18-45 years, BMI ≥ 18.5- 30.\n* Exclusion criteria: Women presenting any uterine disease that affects the endometrial cavity, or with a thin or irregular endometrium, altered karyotypes, thrombophilias, or uncorrected systemic or endocrine diseases will be excluded.\n\nEndometrial receptivity reference group (oocyte donors).\n\n* Inclusion criteria: women aged between 18 and 35 years, BMI ≥ 18.5- 25.\n* Exclusion criteria: Any cases of DIU presence, hormonal contraceptives at least during the last three months, altered karyotypes, thrombophilias, or uncorrected systemic or endocrine diseases will be excluded.",true,"45 Years",{"count":78,"type":21},60,"2 Months","Both controlled ovarian stimulation (COS) and frozen embryo transfer has become an integral part of in vitro fertilization (IVF) treatment. Fresh embryo transfer is usually performed by providing Luteal Phase Support (LPS) with progesterone after COS. Frozen embryo transfer (FET) is usually performed in artificial cycles with hormone replacement treatment (HRT), in which exogenous progesterone is administered, although it can also be performed in a Natural Cycle (without hormone supplementation) (NC). There is evidence that the supraphysiologic levels of estradiol and progesterone during COS+LPS and HRT could lead to morphologic and biochemical endometrial modifications, altering endometrial receptivity and lowering implantation and pregnancy rates.\n\nWe hypothesize that the supraphysiologic hormone levels required for both COS+LPS, and HRT may be inducing alterations in endometrial composition and function, specifically the chronic accumulation of senescent cells; either due to an excessive hormonal induction, a lack of clearance due to a deficit of uNKs, or a combination of both, ultimately affecting both endometrial receptivity and decidualization, worsening IVF outcomes.\n\nThe in vitro clearance of endometrial senescent cells by selective induction of apoptosis has been found to enhance the decidualization capacity of the rest of Endometrial Stromal Cells (EnSC), which could represent in a future adjuvant strategy to reduce the potentially deleterious effects of supraphysiologic hormone levels and improve reproductive outcomes in IVF patients.\n\nThe results derived from this project would have a direct impact on clinical practice. First, the results would allow us to evaluate, based on experimental data, potential endometrial side effects of stimulation protocols commonly used in IVF treatments. In addition, in the case of finding a pathological accumulation of senescent cells affecting endometrial receptivity, we will be able to in vitro evaluate the effectiveness of adjuvant senolytic (drugs designed to specifically remove senescent cells) compounds to in vitro improve the expression of endometrial receptivity markers, as a first step to demonstrate the effectiveness of their use in improving the reproductive outcomes of IVF patients.",[82],"Endometrial Receptivity",[84,85,82,86,87,88,89],"Controled Ovarian Stimulation","Luteal Phase Support","Organoid","Senescence","Senolytic","Single Cell Sequencing","2025-02-25",{"date":92,"type":32},"2025-02-27",{"date":94,"type":32},"2024-02-01",{"date":96,"type":21},"2025-12-30",{"name":38,"class":39},""]